Drug class in one race
JAK1/2 drugs for Atopic Dermatitis
3 tracked JAK1/2 drugs in the Atopic Dermatitis race. The class explanation lives on the JAK1/2 page; the full indication pipeline across every mechanism is on the Atopic Dermatitis page.
1 approved / phase 42 Phase 3
Head-to-head evidence: baricitinib vs Ruxolitinib · pumecitinib vs Ruxolitinib · baricitinib vs pumecitinib